Indivior PLC ADR | |
Stock Exchange | Other OTC |
EPS |
$1.66 |
Market Cap |
$440.65 M |
Shares Outstanding |
146.01 M |
Public Float |
- |
Indivior PLC | |
Stock Exchange | Other OTC |
EPS |
$0.33 |
Market Cap |
$445.14 M |
Shares Outstanding |
728.1 M |
Public Float |
- |
Indivior PLC ADR | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR1.43 |
Market Cap |
EUR370.86 M |
Shares Outstanding |
145.66 M |
Public Float |
- |
Indivior PLC | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
728.31 M |
Public Float |
- |
Indivior PLC | |
Stock Exchange | London Stock Exchange |
EPS |
GBP0.25 |
Market Cap |
GBP352.25 M |
Shares Outstanding |
730.03 M |
Public Float |
724.64 M |
Address |
103-105 Bath Road Slough Berkshire SL1 3UH United Kingdom |
Employees | - |
Website | http://indivior.com/ |
Updated | 07/08/2019 |
Indivior PLC is a holding company, which engages in the manufacture and distribution of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom. |